Funder: Patient-Centered Outcomes Research Institute
Due Dates (Anticipated): May 2026 (Letter of Intent) | September 2026 (Full application)
Funding Amounts: Up to $22 million direct costs per project (feasibility phase: $2M, full-scale study: $20M) over 6.5 years; total funds available up to $120M.
Summary: Supports large, patient-centered comparative effectiveness randomized trials using a two-phase structure with required stakeholder engagement and rigorous trial design.
Key Information: This is a forecasted opportunity; all deadlines are projected and subject to change.